Floatz logo

ct103a cells

POEMS Syndrome

Tongji HospitalCell therapyEarly Phase 1Active
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the POEMS Syndrome cohort.

Asset / SponsorPhaseRating
Fludarabine
Tongji Hospital
Early Phase 1C
Bcma Car T Cells
Zhejiang University
Early Phase 1C
Cyclophosphamide
Tongji Hospital
Early Phase 1C

Same molecule, other indications

ct103a cells is also rated in:

idiopathic inflammatory myopathyDormant
C
Indicative ·
39 / 100
View asset →
chronic inflammatory demyelinating polyradiculoneuropathyDormant
C
Indicative ·
39 / 100
View asset →
autoimmune encephalitisDormant
C
Indicative ·
39 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →